Trial reportFrontiers in immunology2020
Different Innate and Adaptive Immune Responses to SARS-CoV-2 Infection of Asymptomatic, Mild, and Severe Cases.
Trial report in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 125 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
125 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Adaptive immunity to SARS-CoV-2 infection: A systematic review.Frontiers in immunology · 2022Pooled it
- Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection Cases Corroborated by Sequencing.The American journal of tropical medicine and hygiene · 2021Pooled it
- Pooled it
- Pooled it
- Immunothrombosis in Acute Respiratory Dysfunction of COVID-19.Frontiers in immunologyPooled it
- A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome.Nature communications · 2024Trial
- Longitudinal transcriptional analysis of peripheral blood leukocytes in COVID-19 convalescent donors.Journal of translational medicine · 2022Trial
- Integrative Multidimensional Profiling of Individuals Recovered from Mild COVID-19 Reveals Immune-Metabolic-Oxidative Network Interactions.International journal of molecular sciences · 2026Article
- Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases.Nature medicine · 2026Article
- Obesity and COVID-19 severity independently shape adipokine dysregulation and immune cell remodeling.Frontiers in immunology · 2026Article
- Heterogeneous immune recovery after viral response through a dynamical model of feedback-driven persistence and clearance.Frontiers in immunology · 2026Article
- Predicting coronavirus disease 2019 severity using explainable artificial intelligence techniques.Scientific reports · 2025Article
- Early Immune Cell and Antibody Kinetics Following SARS-CoV-2 Vaccination in Healthy Adults and Low-Count Monoclonal B-Cell Lymphocytosis.International journal of molecular sciences · 2025Article
- Innate and adaptive immune patterns in hospitalised COVID-19 patients: a framework for precision monitoring in viral and inflammatory syndromes.Frontiers in immunology · 2025Observational
- SARS-CoV-2 Infections in a Triad of Primary School Learners (Grades 1-7), Their Parents, and Teachers in KwaZulu-Natal, South Africa: Protocol for a Cross-Sectional and Nested Case-Cohort Study.JMIR research protocols · 2024Article
- Cellular immune response to SARS-CoV-2 and clinical presentation in individuals exposed to endemic malaria.Cell reports · 2024Article
- COVID-19's Radiologic, Functional, and Serologic Consequences at 6-Month and 18-Month Follow-up: A Prospective Cohort Study.Journal of Korean medical science · 2024Article
- Impaired immune responses in the airways are associated with poor outcome in critically ill COVID-19 patients.ERJ open research · 2024Article
- Advanced nanomedicines and immunotherapeutics to treat respiratory diseases especially COVID-19 induced thrombosis.World journal of clinical cases · 2024Review
- Titers of IgG and IgA against SARS-CoV-2 proteins and their association with symptoms in mild COVID-19 infection.Scientific reports · 2024Article
65 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SARS-CoV-2 is a novel coronavirus, not encountered before by humans. The wide spectrum of clinical expression of SARS-CoV-2 illness suggests that individual immune responses to SARS-CoV-2 play a crucial role in determining the clinical course after first infection. Immunological studies have focused on patients with moderate to severe disease, demonstrating excessive inflammation in tissues and organ damage. In order to understand the basis of the protective immune response in COVID-19, we performed a longitudinal follow-up, flow-cytometric and serological analysis of innate and adaptive immunity in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.